|
|
IN-DEPTH REPORTS
Proprietary reports on the latest trends in China's pharma industry
EXCLUSIVE INTERVIEWS
Learn what leaders in China's healthcare industry are doing to stay ahead in China
EXECUTIVE NEWS BRIEFS
Most important news briefs from the previous month designed to be read for decision makers
UNIQUE INDUSTRY DATA
Information collected from our revolutionary SOURCE information platform
MONTHLY DELIVERIES
Available in PDF and print format
|
|
|
 |
| |
| Keep track of big picture industry trends |
| |
| The China Pharmaceutical & Biotechnology Review is a monthly publication covering all aspects of the industry, delivered to subscribers via email as a PDF document. From reimbursement policy and industry reform to newly registered drugs and emerging local players, the CPB Review sheds an insightful light on China’s complex and opaque marketplace. Each issue includes news briefs reviewing the key developments of the previous month, in-depth analytical articles, exclusive interviews with industry executives, and research highlights. Included are profiles of companies, products, and influential personalities in the industry. |
| |
| The CPB Review is geared towards healthcare industry professionals interested in keeping track of events in China, but who do not have a pressing need for daily information or historical search capabilities. The CPB Review synthesizes current events and bigger picture trends, making sense of the dizzying pace of change in the Chinese healthcare marketplace. |
| |
 |
| |
| Latest Issues |
| |
|
| Issue 55 |
Lead articles:
Love Me Tender: Shanghai Shuffles Procurement Deck
Private Health Insurance: The Healthcare Financing Option of the Future
Revisiting Breast Cancer Therapies for Greater Efficacy Firth, McHale and Barge on Asia Enabled ASLAN Pharmaceuticals
|
|
|
| Issue 54 |
Lead articles:
Unscripted Outcomes: Shanghai Pilots Prescription-Free Rx Sales
Raising the Bar: New GMP Clears Competitive Landscape
c-MET Inhibitor Programs in China Seeking Answers for Cancer Joseph McCracken on Business Development for Pharma Companies in China
|
|
|
| Issue 53 |
Lead articles:
Ending drug markups: Saved by Zero? Or no Fix at all?
Schizophrenia Treatment in China: A brief look
Binhui Ni on R&D Partnering Business in China
|
|
|
|
